About: Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID‐19, in Healthy Subjects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID‐19, in Healthy Subjects Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID‐19, in Healthy Subjects
Creator	German, Polina Cao, Huyen Chng, Estelle Humeniuk, Rita Ling, John Mathias, Anita Osinusi, Anu Shen, Gong Vu, Amanda
Source	Medline; PMC
abstract	Remdesivir (RDV), a single diastereomeric monophosphoroamidate prodrug that inhibits viral RNA polymerases, has potent in vitro antiviral activity against SARS‐CoV2. RDV received FDA’s emergency use authorization in United States and approval in Japan for treatment of severe COVID‐19 patients. This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of single escalating and multiple intravenous (IV) doses of RDV (solution or lyophilized formulation) in healthy subjects. Lyophilized formulation was evaluated for potential future use in clinical trials due to its storage stability in resource‐limited settings. All adverse events were Grade 1 or 2 in severity. Overall, RDV exhibited a linear profile following single‐dose IV administration over 2 hours of RDV solution formulation across the dose range of 3 to 225mg. Both lyophilized and solution formulations provided comparable PK parameters. High intracellular concentrations of the active triphosphate (approximately 220 to 370‐ fold higher than the in vitro EC50 against SARS‐CoV‐2 clinical isolate) were achieved following infusion of 75 mg or 150 mg lyophilized formulation over 30 minutes or 2 hours. Following multiple‐doses of RDV 150mg once daily for 7 or 14 days, RDV exhibited a PK profile similar to single‐dose administration. Metabolite GS‐441524 accumulated approximately 1.9‐fold after daily dosing. Overall, RDV exhibited favorable safety and PK profiles that supported once‐daily dosing.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1111/cts.12840
bibo:pmid	32589775
has license	cc-by-nd
sha1sum (hex)	e592e1c7cab5f7d430288a5f6b08ba710fc5f170
schema:url	https://doi.org/10.1111/cts.12840
resource representing a document's title	Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID‐19, in Healthy Subjects
has PubMed Central identifier	PMC7361781
has PubMed identifier	32589775
schema:publication	Clin Transl Sci
resource representing a document's body	covid:e592e1c7cab5f7d430288a5f6b08ba710fc5f170#body_text
is schema:about of	named entity 'sample size' named entity 'NOAEL' named entity 'acute respiratory distress syndrome' named entity 'steady state' named entity 'fever' named entity 'ALT' named entity 'prodrug' named entity 'SAEs' named entity 'Japan' named entity 'COVID' named entity 'PBMC' named entity 'placebo' named entity 'terminal elimination half-life' named entity 'diarrhea' named entity 'rat' named entity 'C max' named entity 'CoV' named entity 'urinalysis' named entity 'GS-441524' named entity 'hepatitis C virus' named entity 'metabolic' named entity 'COVID-19' named entity 'GS-441524' named entity 'Hispanic' named entity 'GS-441524' named entity 'phosphorylated' named entity 'pneumonia' named entity 'respiratory disease' named entity 'pregnancy' named entity 'prothrombin time' named entity 'rhesus monkeys' named entity 'lyophilized' named entity 'WHO' named entity 'SARS-CoV-2' named entity 'IV administration' named entity 'Constipation' named entity 'SARS-CoV-2' named entity 'categorical data' named entity 'antiviral activity' named entity 'Remdesivir' named entity 'COVID' named entity 'blood donation' named entity 'remdesivir' named entity 'physical examinations' named entity '12-lead' named entity 'US Food and Drug Administration' named entity 'virulent' named entity 'first-in-human' named entity 'fatigue' named entity 'headache' named entity 'placebo-controlled' named entity 'RNA' named entity 'ecchymosis' named entity 'DAIDS' named entity 'CoV' named entity 'remdesivir' named entity 'Phase 1' named entity 'AEs' named entity 'AEs' named entity 'severe acute respiratory syndrome coronavirus' named entity 'constipation' named entity 'physical examinations' named entity 'antiviral agent' named entity 'viral disease' named entity 'Public Health Emergency of International Concern' named entity 'adverse events' named entity 'metabolite' named entity 'Middle Eastern respiratory syndrome coronavirus' named entity 'sequence identity' named entity 'pruritus' named entity 'nucleoside analog' named entity 'IV administration' named entity 'toxicology'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software